Edgewise Therapeutics, Inc.
EWTX
株式のランク
#3979
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
株価
$38.12
最終同期: 2026-10-19
時価総額
$4.10B
変化（1日）
2.50%
変化（1年）
147.69%
国
US
取引 Edgewise Therapeutics, Inc. (EWTX)
カテゴリー
Healthcare
Edgewise Therapeutics, Inc.（EWTX）のP/S比率
October 2026 時点のP/S比率 TTM: 0.00
Edgewise Therapeutics, Inc. の最新の財務報告および株価によると、現在のP/S比率（TTM）は 0.00 です。2023 年末時点でのP/S比率は 0.00 でした。
Edgewise Therapeutics, Inc. の P/S 比率の履歴（2019 ～ 2026）
各年末時点のP/S比率
| 年 | P/S比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
同業他社のP/S比率
| 企業 | P/S比率 | P/S比率の差 | 国 |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
